Effect of probiotics on giardiasis. Where are we?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/153811 |
Resumo: | Giardiasis, an intestinal infection caused by Giardia lamblia, was recently included in the ‘Neglected Diseases Initiative’ by the World Health Organization. Symptomatic patients can develop mild diarrhea up to a severe malabsorption syndrome, and children may show significantly impaired cognitive and physical development. Currently, nitroimidazoles are the main class of antibiotic used to treat giardiasis. Despite the efficacy of these drugs, adverse effects and reported resistance have increased, encouraging studies to identify and develop therapeutic alternatives. In this context, probiotics may represent an attractive option. Probiotics are defined as live microorganisms that, when administered in suitable amounts, confer a health benefit to the host. The use of probiotics in the treatment of parasitosis has been suggested because of its beneficial effects, such as a reduced time of gastrointestinal symptoms and parasite load in animal models and humans. Probiotics have been studied as an alternative treatment for giardiasis. In this review, we evaluated probiotic effectiveness in the treatment and prevention of this disease. Based on the studies examined herein, we conclude that probiotics have a beneficial effect on the modulation of giardiasis. |
id |
USP-31_1437a60cd50e41ce3227244dd2c080bf |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/153811 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
Effect of probiotics on giardiasis. Where are we?Giardia lambliaGiardiasisProbiotics/effects/evaluationGiardiasis, an intestinal infection caused by Giardia lamblia, was recently included in the ‘Neglected Diseases Initiative’ by the World Health Organization. Symptomatic patients can develop mild diarrhea up to a severe malabsorption syndrome, and children may show significantly impaired cognitive and physical development. Currently, nitroimidazoles are the main class of antibiotic used to treat giardiasis. Despite the efficacy of these drugs, adverse effects and reported resistance have increased, encouraging studies to identify and develop therapeutic alternatives. In this context, probiotics may represent an attractive option. Probiotics are defined as live microorganisms that, when administered in suitable amounts, confer a health benefit to the host. The use of probiotics in the treatment of parasitosis has been suggested because of its beneficial effects, such as a reduced time of gastrointestinal symptoms and parasite load in animal models and humans. Probiotics have been studied as an alternative treatment for giardiasis. In this review, we evaluated probiotic effectiveness in the treatment and prevention of this disease. Based on the studies examined herein, we conclude that probiotics have a beneficial effect on the modulation of giardiasis.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2018-07-26info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/15381110.1590/s2175-97902018000217360Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 2 (2018); e17360Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 2 (2018); e17360Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 2 (2018); e173602175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/153811/150191Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessVentura, Luciana Laranjo AmorimOliveira, Dirce Ribeiro deGomes, Maria AparecidaTorres, Marcia Regina Fantoni2019-03-17T14:04:07Zoai:revistas.usp.br:article/153811Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2019-03-17T14:04:07Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Effect of probiotics on giardiasis. Where are we? |
title |
Effect of probiotics on giardiasis. Where are we? |
spellingShingle |
Effect of probiotics on giardiasis. Where are we? Ventura, Luciana Laranjo Amorim Giardia lamblia Giardiasis Probiotics/effects/evaluation |
title_short |
Effect of probiotics on giardiasis. Where are we? |
title_full |
Effect of probiotics on giardiasis. Where are we? |
title_fullStr |
Effect of probiotics on giardiasis. Where are we? |
title_full_unstemmed |
Effect of probiotics on giardiasis. Where are we? |
title_sort |
Effect of probiotics on giardiasis. Where are we? |
author |
Ventura, Luciana Laranjo Amorim |
author_facet |
Ventura, Luciana Laranjo Amorim Oliveira, Dirce Ribeiro de Gomes, Maria Aparecida Torres, Marcia Regina Fantoni |
author_role |
author |
author2 |
Oliveira, Dirce Ribeiro de Gomes, Maria Aparecida Torres, Marcia Regina Fantoni |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Ventura, Luciana Laranjo Amorim Oliveira, Dirce Ribeiro de Gomes, Maria Aparecida Torres, Marcia Regina Fantoni |
dc.subject.por.fl_str_mv |
Giardia lamblia Giardiasis Probiotics/effects/evaluation |
topic |
Giardia lamblia Giardiasis Probiotics/effects/evaluation |
description |
Giardiasis, an intestinal infection caused by Giardia lamblia, was recently included in the ‘Neglected Diseases Initiative’ by the World Health Organization. Symptomatic patients can develop mild diarrhea up to a severe malabsorption syndrome, and children may show significantly impaired cognitive and physical development. Currently, nitroimidazoles are the main class of antibiotic used to treat giardiasis. Despite the efficacy of these drugs, adverse effects and reported resistance have increased, encouraging studies to identify and develop therapeutic alternatives. In this context, probiotics may represent an attractive option. Probiotics are defined as live microorganisms that, when administered in suitable amounts, confer a health benefit to the host. The use of probiotics in the treatment of parasitosis has been suggested because of its beneficial effects, such as a reduced time of gastrointestinal symptoms and parasite load in animal models and humans. Probiotics have been studied as an alternative treatment for giardiasis. In this review, we evaluated probiotic effectiveness in the treatment and prevention of this disease. Based on the studies examined herein, we conclude that probiotics have a beneficial effect on the modulation of giardiasis. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-07-26 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/153811 10.1590/s2175-97902018000217360 |
url |
https://www.revistas.usp.br/bjps/article/view/153811 |
identifier_str_mv |
10.1590/s2175-97902018000217360 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/153811/150191 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 2 (2018); e17360 Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 2 (2018); e17360 Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 2 (2018); e17360 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222913746436096 |